Home
TVRD
TVRD News

Latest Tvardi Therapeutics Inc. Common Stock (TVRD) News on November 26, 2025

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks

7 days ago

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Business Wire

8 days ago

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Associated Press Finance

12 days ago

Tvardi: Q3 Earnings Snapshot

Business Wire

12 days ago

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Business Wire

22 days ago

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround

Zacks

a month ago

Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals

Zacks

a month ago

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals

AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance

BioPharma Dive

a month ago

AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance

Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results

Simply Wall St.

a month ago

Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results

MT Newswires

a month ago

Top Midday Decliners

MT Newswires

a month ago

Barclays Initiates Tvardi Therapeutics at Overweight With $61 Price Target

MT Newswires

a month ago

Sector Update: Health Care Stocks Higher Premarket Monday

MT Newswires

a month ago

Tvardi Therapeutics' Potential Lung Disease Treatment Fails to Meet Goals; Shares Decline Pre-Bell

Business Wire

a month ago

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26%

Simply Wall St.

a month ago

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26%

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

TipRanks

6 months ago

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

Business Wire

6 months ago

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Business Wire

6 months ago

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

Business Wire

6 months ago

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Business Wire

7 months ago

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Share on Social Networks: